· To include patients with a qualifying IOP increase as a result of steroid therapy administered by any route (excluding fluocinolone acetonide ocular implants), intravitreal or periocular injection,topical ocular, other topical administration, inhaled or chronic systemic.

· Patients with an IOP of at least 24 mmHg.

· Patients with an IOP increase ≥ 10 mmHg relative to their pre-intravitreal steroid therapy IOP.

· If patients are on hypotensive medications, they must have at least 30 days of stable dosing prior to screening.

· Other inclusion criteria per the study coordinator.

· History of ocular trauma within the past 6 months in the study eye.

· Patients with a history of penetrating glaucoma surgery (i.e. trabeculectomy,valves,etc.) in the study eye.

· Patient has had an insertion of a scleral buckle in the study eye.

· Patients with a cup/disc ratio greater than 0.80 (horizontal or vertical measurement) in either eye

· Any abnormality preventing reliable applanation tonometry of the study eye.

· Clinical evidence of scleral thinning.

· Contact lens wearers who are not willing to discontinue use during the course of the study.

· Other exclusion criteria per the study coordinator.

· Patients who are on intravenous or subcutaneous anticoagulant therapy, or on oral anticoagulant therapy, (with the exception of aspirin and antiplatelet therapy) and cannot take a 5 day interruption in therapy prior to the injection procedure.

· Patients with a known medical history of allergy to the steroid family of drugs.

· Patients with a known medical history of allergy to the steroid family of drugs.

· Other exclusion criteria per the study coordinator.